XCEL SALES MATERIALS DRAW DDMAC LETTER

Washington Drug Letter
KEYWORDS Advertising / FDA
A A

The FDA has told Xcel Pharmaceuticals that its promotional materials for two migraine products omit risk information, make misleading comparative claims about safety and include unsubstantiated efficacy and indication claims.

To View This Article:

Login

Buy This Article Now

Add this article to your cart for $10.00